The expression of Nonmuscle Myosin Heavy Chain B (SMemb) in Rat Allogeneic Kidney Transplantation Models

研究人员已报道，非肌球蛋白重链B(SMemb)在各种类型的肾小球疾病中表达增强，这些疾病发展为肾硬化症。在肾移植中，移植肾小球炎通常在急性排斥反应中被发现。因此，我们推测SMemb在急性排斥反应中起重要作用。为了评价SMemb在肾排斥反应中的作用，我们检测了SMemb在大鼠肾移植模型中的表达。我们使用Lewis大鼠作为受体，Wister大鼠作为供体。I组：对照组。II组：同种异体移植模型。Ⅲ组：同种异体移植模型。IV组：III组+环孢素A(CsA)10 mg/kg/d。V组：III组+CsA组，术后5d。组织病理学和SMemb免疫组织化学研究均已完成。I、II、IV、V组肾小球细胞中仅见少量SMemb表达。但在CsA治疗终止后，SMemb的表达增加。SMemb的表达高于同种异体移植模型和CsA处理模型。免疫组织化学研究表明，SMemb在早期即有明显表达，几乎没有组织病理学反应。因此，这可能有助于急性排斥反应的早期诊断。

Investigators have reported that nonmuscle myosin heavy chain B (SMemb) expression is enhanced in various types of glomerular diseases which develop into nephrosclerosis. In renal transplantation, transplant glomerulitis is often recognized during acute rejection. Therefore, we hypothesized that SMemb plays important roles in acute rejection kidney. To evaluate the role of SMemb in the development of kidney rejection, we examined its expression in rat kidney transplantation models. We used Lewis rats as recipients and Wister rats as donors. Group I ; control. Group II ; isograft model. Group III ; allograft model. Group IV ; group III+10 mg/kg/day of Cyclosporine A (CsA). Group V ; group III+CsA administration for 5 days post operation. Histopathological and SMemb immunohistochemical studies have done. Clear enhancement of SMemb expression was found on day 3 in group III.In group I, II, IV and V, SMemb was faintly expressed in the glomerular cells. However after termination of CsA treatment, SMemb expression was increased. The expression of SMemb was higher than that in both isografts and CsA-treated models. Immunohistological investigations show that SMemb expression was significant from an early stage where histopathological reactions were hardly seen. This, therefore, could be useful for earlier diagnosis of acute rejection.